Literature DB >> 9030693

The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain.

M Yamada1, K Groshan, C T Phung, M Yamada1, T Hisamitsu, E Richelson.   

Abstract

We molecularly cloned the kappa opioid receptor from a human substantia nigra cDNA library. When expressed in HEK293 cells, the cloned receptor had similar pharmacological characteristics to the rat kappa opioid receptor. Northern blot analysis showed the presence of a single transcript of about 6 kb in size for mRNA prepared from the substantia nigra. Using in situ hybridization histochemistry, we studied the expression of this receptor in postmortem human brains from control and Parkinson's disease subjects. Kappa opioid receptor mRNA was present in melanized (possibly dopaminergic) neurons of the substantia nigra and the nucleus paranigralis. On the other hand, Parkinson's disease brains had markedly fewer melanized neurons, as expected, and correspondingly very low or background levels of mRNA for the kappa opioid receptor. However, in some cases, remaining melanized neurons still expressed the receptor mRNA. From these results we suggest that dopaminergic neurons in the human substantia nigra and the nucleus paranigralis synthesize kappa opioid receptors and express them in their perikarya and their terminal regions. The kappa opioid receptor expressed in the melanized neurons may play a role in the normal function of dopaminergic systems and possibly in the etiology of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030693     DOI: 10.1016/s0169-328x(96)00139-8

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  2 in total

1.  Tau Protein Levels in ADHD.

Authors:  Keith Fluegge
Journal:  Indian J Clin Biochem       Date:  2018-04-19

2.  Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics.

Authors:  Yang Sheng; Emily Filichia; Elizabeth Shick; Kenzie L Preston; Karran A Phillips; Leslie Cooperman; Zhicheng Lin; Paul Tesar; Barry Hoffer; Yu Luo
Journal:  Brain Behav       Date:  2016-05-25       Impact factor: 2.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.